NEW YORK, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 4th annual OktoberINVESTfest investors conference on Tuesday, October 13, 2015 at 2:30 p.m. ET. The Conference will be held at The New York Academy of Sciences in New York City.
In his presentation, Dr. Missling will provide an overview of Anavex’s ongoing Phase 2a clinical trial of ANAVEX™ 2-73 in Alzheimer’s patients. Full PART A and preliminary PART B Phase 2a clinical trial data will be presented at the CTAD conference on November 7, 2015.
OktoberINVESTfest brings together US and German investors, innovators, industry leaders, Bavarian state representatives as well as a number of innovative North American and German companies. The resulting business and investment ties will deepen transatlantic relations and encourage economic and scientific exchange.
* Anavex’s stock is temporarily trading under the ticker AVXLD.
About Anavex™ Life Sciences Corp.
Anavex™ Life Sciences Corp. (OTCQX:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. Initial positive data was presented at AAIC 2015 and full PART A and preliminary PART B Phase 2a clinical trial data will be presented at CTAD in November 2015. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties indicating its potential to treat additional CNS disorders. Further information is available at www.anavex.com.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex™ Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information Anavex™ Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: email@example.com Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: firstname.lastname@example.org www.anavex.com
Source:Anavex Life Sciences Corp.